Objective. To compare the efficacy of hydroxychloroquine, penicillamine, sodium aurothiomalate and auranofin in the treatment of active rheumatoid arthritis over a period of 5 yr.
I clinical practice, disease-modifying anti-rheumatic penicillamine, injectable gold and oral gold (auranofin), had a mean duration of follow-up of only 39 drugs (DMARDs) are an important therapeutic option in the medical management of patients with active weeks, thus the conclusions may not reflect longer term treatment outcomes. The question of the comparative progressive rheumatoid arthritis (RA) [1, 2] . These drugs are prescribed either alone, sequentially or in benefits and safety of each of these four DMARDs, based on data from randomized controlled trials combination over many years, with the aim of maintaining good control of symptoms and suppressing extended beyond 2 yr, remains unanswered because the combination of a high drop-out rate and the large disease activity [3, 4] , reducing the risk of relapse [5, 6 ] and preventing long-term disability [7] [8] [9] .
number of patients required in each treatment group The comparative efficacy and safety of DMARDs, presents major logistical problems. Nevertheless, there as evidenced by the results of prospective, randomized is a justified expectation from patients, rheumatolocontrolled trials, have not generally been established gists, family practitioners and the pharmaceutical for treatments lasting for longer than 2 yr [10] [11] [12] [13] [14] [15] .
industry that reliable evidence of comparative effectHowever, while studies report almost 50% of patients iveness should be available while these drugs continue discontinuing treatment with hydroxychloroquine, to be prescribed over many years. penicillamine or gold within this time due to lack or Sulphasalazine and methotrexate are now the loss of efficacy or adverse reaction [16, 17] , in clinical DMARDs of first choice for the treatment of active practice some patients can be maintained successfully RA, but, despite this recent change in prescribing on each of these DMARDs for between 2 and 5 yr, or patterns, hydroxychloroquine, penicillamine and gold longer [8, [18] [19] [20] .
salts continue to be prescribed in clinical practice [2, The difficulties of evaluating the relative merits and 23, 24] . safety of the available DMARDs have been critically
The prospective randomized controlled trial reviewed [21, 22] . Two meta-analyses, based on randescribed here was designed with the primary objective domized controlled studies of seven commonly preof determining the effectiveness of hydroxychloroquine, scribed DMARDs, including hydroxychloroquine, penicillamine and gold in a clinical setting, by establishing the proportion of patients who stayed on their first DMARD for 5 yr, or who were in remission. The between these four DMARDs in clinical, laboratory, judged by an increase in the Larsen score [30] over the preceding 12 months. Patients on corticosteroids functional and radiological assessments of patients maintained on their first DMARD for 5 yr.
for arthritis were eligible for inclusion provided the dose did not exceed 10 mg/day for 3 months prior to PATIENTS AND METHODS entry. Intra-articular steroids were permitted as clinically indicated, and the site, the dosage and number of
Study design
The study was designed in 1980, and a written injections were recorded. There was an interval of at least 4 weeks between the joint injections and any protocol was approved by the district research ethics committee. Recruitment began in 1981. This was an assessment. Exclusion criteria included pregnancy or planned open randomized prospective comparison of three DMARDs: hydroxychloroquine, penicillamine and pregnancy, severe functional disability-Steinbrocker stage 4 [25] , severe joint damage or ankylosis on sodium aurothiomalate. In 1983, a fourth DMARD, auranofin, was added to the gold arm of the study.
radiographs of the hands and/or feet, or any co-existing medical or psychological condition which might prejuPatients who stayed on active therapy with one of the study drugs were assessed at 6 monthly intervals for dice compliance with the trial protocol. The sample size required for each of the three major 5 yr. Clinical assessments included: (i) pain visual analogue scale ( VAS ) (0-10 cm); (ii) duration of arms of the study, hydroxychloroquine, penicillamine and gold (subdivided in 1983 into injectable and oral ), morning stiffness (min); (iii) grip strength (mmHg): mean of three readings for right and left hands; (iv) was calculated to be 126 patients [31] . This was based on a power of 90% to detect a difference of 20 Steinbrocker functional grade [25] ; (v) patient assessment of response to treatment compared with previous percentage points (40-60%) in the proportion staying on their initial DMARD for 5 yr, with a conventional 6 month visit. From 1983, a joint tenderness score, the Ritchie Articular Index [26 ] and Health Assessment a level of 0.05. A larger number of patients was recruited because it was anticipated that a substantial Questionnaire [27] were added. Laboratory assessments included full blood count, Westergren's erythroproportion of patients would fail to remain in the study [32] . cyte sedimentation rate ( ESR), C-reactive protein (CRP) and rheumatoid factor. Patients who had to Randomization between 1981 and 1983 was by means of a series of open cards which detailed the stop treatment due to lack of effect or adverse reactions were randomized to a second or third DMARD, and choice of DMARD for the first 120 patients. From 1983 to 1989, the randomization procedure was monitored using the same trial protocol. Decisions to withdraw from the study were taken by the patient changed to a sequence of sealed envelopes for the remaining 421 patients. This ensured that the physician, and the managing physician. All patients were recalled for a final assessment 5 yr after entry. Recruitment of monitor clinic rheumatologist and patient were all unaware of the choice of DMARD prior to enrolment. new patients ended in 1989, and the final assessments were completed in 1994.
Analysis confirmed that there were no important differences in the disease activity and severity of This was a single-centre study, conducted in the rheumatology department of the University Hospital patients allocated treatment with each DMARD prior to this change in the method of randomization. of Wales in a dedicated weekly monitor clinic staffed by two rheumatologists (JDJ and an experienced senior Following the introduction of auranofin, patients in the gold arm of the study had an equal chance of trainee), the same two metrologists throughout the whole study, a research assistant and a trial nurse. receiving either sodium aurothiomalate or auranofin. The annual rate of recruitment was constant throughClinical assessments were completed by the same metrologist on each visit whenever possible. The reliout the study at~70 patients, and no important temporal changes were identified in the characteristics ability of the metrologists for scoring the Ritchie Articular Index was reported in a separate study [28] .
of the patients on entry [33] . All monitor clinic staff were responsible for ensuring strict adherence to the trial protocol, and for assessing Outcome measures The primary outcome measure was the proportion and documenting measurements of disease activity and severity at each monitor clinic visit. The majority of of patients who remained on their first DMARD for 5 yr, or who were in complete or near-remission. patients were referred from family practitioners in South Glamorgan.
Remission was defined as complete if the criteria of the American Rheumatism Association were fulfilled Entry criteria specified that all patients should be aged between 16 and 70 yr, and have classical or [34] . Near-remission was defined in this study as a combination of a Ritchie score of <10, minimal joint definite RA [29] . All had active disease inadequately controlled by at least two different non-steroidal antipain and stiffness requiring intermittent or no analgesics and/or NSAIDs, functional class 1 and an ESR inflammatory drugs (NSAIDs) for at least 6 months and had not previously been treated with DMARDs.
of <28 mm/h or a CRP of <6 mg/l. The decision whether or not to stop treatment due Active disease was defined by a minimum of three of the following criteria: (i) six painful joints; (ii) three to lack or loss of effect was based primarily on clinical judgement, with agreement between the managing swollen joints; (iii) ESR > 28 mm/h; (iv) morning stiffness > 45 min; (v) radiological progression as physician and the patient that the DMARD was not effective. To reduce the risk of bias in this open study, continued for 5 yr on the DMARD to which they were initially randomized. this decision required confirmation from the monitor clinic rheumatologist on a second clinic visit that there The proportion of patients in different outcome groups was compared using the x2 test. As this analysis was evidence of persisting lack of effect. When, in 1983, auranofin was added to the study, the trial treats withdrawals as being failures, a standard cohort life table was also calculated to produce multiple protocol was strengthened by defining the following additional criteria that were subsequently used by the decrements to describe the proportion of patients in the different outcome groups over 5 yr [38] . This monitor clinic rheumatologist to decide that a DMARD was insufficiently effective: (i) new joint provides a slightly different picture of the results shown in Fig. 1 when compared with those presented below. involvement; (ii) no improvement after two different untried NSAIDs; (iii) rising ESR/CRP; (iv) no lasting
The database used to manage the data was ORACLE, and the statistical package SPSS was used for the relief following repeated intra-articular steroid injections; (v) progressive radiological deterioration. The analysis. clinical assessment of failure was supported by at least two out of these additional five criteria from 1983 until Drug therapy The protocols for each of the four DMARDs were the end of the study.
The primary outcomes can be categorized into four agreed between all of the participating rheumatologists, and with each appropriate pharmaceutical company main groups: (i) continuation of the initial DMARD for 5 yr and/or remission; (ii) withdrawal from the prior to the start of the study. Patients were kept on their initial DMARD if possible for at least 6 months, study; (iii) failure due to adverse event; (iv) failure due to lack or loss of effect, or death.
and preferably for the full 5 yr, using a flexible dosage regimen and the minimum dose consistent with mainSecondary outcome measures concerned changes in the clinical, laboratory, functional and radiological taining a satisfactory clinical response or remission. The patient, physicians and metrologists were all aware assessments. Because the time intervals between the initial and final assessments could vary for practical of the treatment that was being prescribed. Hydroxychloroquine (Plaquenil ) was prescribed in reasons, the 5 yr change in these variables was derived by linear interpolation from the data collected, with a a dose of 400 mg daily, with the option to reduce to 200 mg if the daily dose exceeded 6.5 mg/kg body minimum duration of follow-up of 4.5 yr.
weight [39] . Studies from this department have confirmed the safety of this regimen with regard to the Radiology Radiographs of hands and feet were taken at annual eye for patients on treatment for <5 yr [40, 41] . The mean daily dose for this group was 396 mg (range intervals and also after discontinuation of DMARD treatment; the same high-definition film/screen com-200-400 mg) at study exit (n = 49). Penicillamine (Distamine) was commenced at bination was employed throughout the study period.
Films were scored according to the method of Larsen 125 mg daily and increased in a gradual responserelated flexible regimen by 125 mg every 4 weeks to a et al. [30] by an experienced bone and joint radiologist (LAW ), who was unaware of the clinical details. Each maximum of 500 mg daily [42] . The managing physician had the option to keep the dose to the minimum film was graded with reference to previous films, as paired readings have been shown to be more accurate required to maintain good control of disease activity. The mean daily dose at study exit for this group than separate readings [35] . The precision of the scoring method in this department was evaluated in a (n = 94) was 396 mg (125-500 mg). Sodium aurothiomalate (Myocrisin) was given as a separate study [36 ] .
The following 32 joints were scored: eight proximal test dose of 10 mg followed by 50 mg weekly to a total of 500-1000 mg, depending on the clinical response, interphalangeal (PIP); two interphalangeal (IP) thumb; 10 metacarpophalangeal (MCP); two wrists; reduced to 50 mg every 2 weeks to a total of 1 g, and 50 mg monthly for the rest of the study. The dose two hallux IP and eight second to fifth metatarsophalangeal (MTP). Each wrist was scored as a unit and could be increased from 50 mg every 4 weeks to 50 mg every 2 weeks if there was evidence of lack of efficacy, then multiplied by five [37] . The first MTP joint was excluded because it is frequently affected by or decreased to 20 mg every 6 weeks if disease activity was well controlled. The mean dose (mg/month) for osteoarthritis. The maximum possible total Larsen score was therefore 200.
patients receiving sodium aurothiomalate for 5 yr (n = 38) was 48.9 mg (13-100 mg) at study exit.
Auranofin was prescribed as 6 mg daily in a single
Data administration and analysis
Great care was taken to ensure accuracy when dose and the only variation permitted in the trial protocol was to split the dose to 3 mg twice daily in transcribing data from the monitor clinic notes to the computer file, with frequent liaison between administhe event of drug-induced diarrhoea. The mean daily dose for this group (n = 22) was unchanged at 6 mg. tration and monitor clinic staff, especially when checking unexpected results. Most analyses were based on the intention-to-treat principle, but a more detailed
Monitoring and management of adverse events Possible adverse reactions were reported by the analysis was carried out of adverse reactions, deaths and of the characteristics of the subset of patients who patient to the family practitioner, referring physician or monitor clinic rheumatologist, and the decision to sible drug-induced eye effects vary between countries [44] , policies are currently being reviewed, and our stop the second-line drug temporarily or permanently was agreed with the monitor clinic rheumatologist. For practice was consistent with a relaxation of eye monitoring guidelines in this country [45] . minor abnormalities, treatment was stopped temporarily until a return to normal, and then cautiously reintroduced in reduced dosage if the trial criteria for active arthritis were fulfilled. Any recurrence of signifiGold and penicillamine Haematological and renal criteria for permanently cant toxicity, based on clinical judgement, led to that DMARD being stopped. stopping oral gold, i.m. gold or penicillamine were: platelet count of <120 × 109/l, white cell count of Major adverse effects were covered by an agreed shared-care protocol for each drug, which was avail-<4.0 × 109/l, neutrophils <2.0 × 109/l, urine protein dipstick ++ on two consecutive visits with 24 h urine able in the department and to family practitioners.
protein >1 g in the absence of any other pathology.
Hydroxychloroquine
All patients had a detailed eye examination either by a consultant ophthalmologist or a senior ophthalOther anti-rheumatic drugs In addition to the DMARDs, NSAIDs and analmology trainee before or within 3 months of starting treatment. During the early years of the study, detailed gesics were prescribed routinely and dates of changes of treatment and dosages recorded. The protocol ophthalmic surveillance was continued annually in the eye department. Following reports of the safety of allowed oral prednisolone to be prescribed in a dosage up to 10 mg daily, but represented a failure of hydroxychloroquine on the eye with dosages of <6.5 mg/kg body weight [43] , the study protocol was DMARD treatment and required stopping this DMARD. If dosages >10 mg were prescribed, the altered to an initial ophthalmic examination only, and subsequent referral to the eye department only if a patient was withdrawn from the study, but still followed up at 5 yr. Intra-articular methylprednisolone possible drug-related abnormality was suspected. Although recommendations for monitoring for posinjections were permitted as clinically indicated. RESULTS cillamine were still taking this DMARD at 5 yr (95% CI 46-60%). The proportions of patients continuing The characteristics of the 541 patients at entry to on the other DMARDs were significantly lower: 34% the study are as shown in Table I . The results show (CI 26-43%) for sodium aurothiomalate, 31% (CI that patients had active disease of relatively short 21-43%) for auranofin and 30% (CI 23-37%) for duration (median 2 yr) prior to receiving their initial hydroxychloroquine [x2 = 23.5 (3 d.f.), P < 0.001]. DMARD, and that the majority were seropositive for One hundred and twenty-three patients developed rheumatoid factor (76%), with an erosive arthropathy an adverse reaction as defined in the trial protocol, on radiographs of hands and/or feet (82%). There which required stopping treatment. Almost all of these were no important differences between the treatment were specific reactions as defined in the protocol, but groups in terms of the demographic features, or in the in a few cases the relationship to drug treatment was measures of disease activity and severity.
doubtful ( Table III ) . This group included one patient The outcomes have been classified under four main who developed a transient proteinuria while on hydroxycategories ( Table II ) . Only 6% of patients were withchloroquine and six patients who developed nondrawn from the study. One hundred and ninety-four specific symptoms which only resolved after stopping patients were maintained on their initial randomized treatment. The two patients who stopped hydroxy-DMARD throughout the 5 yr study period, with 6 chloroquine because of ophthalmic abnormalities were monthly assessments according to the trial protocol.
subsequently re-examined by a consultant ophthalmoAn additional 11 patients voluntarily declined to attend logist and re-classified as having had a pre-existing the formal study visits, but continued to take their abnormality in the eye unrelated to drug treatment. DMARDs in the recommended dosages and attended An additional three patients chose to stop treatment for a final 5 yr end-of-study assessment. In a further after minor drug reactions, bringing the total number five patients, treatment was stopped prematurely, either of patients who stopped treatment due to adverse by the patient or by the managing physician, because events to 126 (23%). of disease remission. One patient was in complete A total of 173 patients (32%) failed to complete the remission and four patients were in near-remission. All study because of lack or loss of effect, or death. Of five patients attended for their 5 yr assessment when the 16 patients who died, no deaths were attributable remission was confirmed. This brought the total either to RA or to treatment with any of the four number of patients who had taken their first DMARD second-line drugs ( Table IV ) . One hundred and thirty for 5 yr, or who had stopped treatment due to remispatients failed to respond, or to maintain an adequate sion, to 210 (39%).
Fifty-three per cent of patients randomized to peniresponse by fulfilling the trial failure criteria, and For the other variables, the frequency of missing data was <0.6%, except for plasma viscosity (8%), platelets (6%) and Larsen score (1.8%). This table shows how the various outcomes from the study, including deviations from the protocol, were categorized in terms of continuation on the initial DMARD into success or failure or withdrawal from the study.
*One patient was in complete remission by ARA criteria. stopped treatment. An additional 18 patients stopped of severity and clinical course, as RA is difficult, but the length of time that patients remain on antitreatment due to lack of effect which was either confirmed at final review in those who attended (nine) or rheumatic therapy is accepted as a surrogate measure of the effectiveness of treatment [21] . Using this outconfirmed on review of the hospital medical records (nine). Four patients were inadvertently treated with come measure, we found that penicillamine was superior to hydroxychloroquine, sodium aurothiomalate and an alternative DMARD outside the trial protocol.
The proportion of patients who failed to remain on auranofin. Uniformity of the different treatment groups at treatment for 5 yr due either to lack or loss of effect, or to an adverse reaction, is summarized for each of baseline is a prerequisite for comparative studies, and can only be achieved by random allocation to treatthe four treatments in the multiple decrement analysis ( Fig. 1) . For patients taking hydroxychloroquine, the ment. The randomization procedure adopted in this trial protects against treatment allocation bias, and majority of failures occurred during the first 18 months due to lack of effect. For patients treated with injectable has produced four groups which were comparable at entry in terms of demographics, conventional disease or oral gold preparations, the majority of failures occurred during the first 2 yr, with most of the failures activity and severity indices, and confirmed that patients with active, nodular, seropositive and erosive for those on injectable gold due to adverse reactions, while for those on auranofin the failures were almost arthritis were equally distributed between the groups ( Table I ) . The decision to divide the gold arm into equally distributed between adverse reactions and lack of effect. For those on penicillamine, 69% of patients separate groups for i.m. and oral gold was taken because of uncertainty at the time the trial was being were still on active treatment after 2 yr, and there was a steady drop-out from both lack of effect and adverse designed of the risks of adverse cross-reactions between the two formulations of gold. As the gold-treated reactions throughout the 5 yr duration of the study. Table V shows the 5 yr changes in clinical, laborapatients had to be analysed separately, the reduction in numbers in each group has weakened the ability to tory, functional and radiological measures of disease activity and severity for the subgroups of patients detect differences between the gold groups and the other DMARDs. However, the experience gained by remaining on their initial DMARD for the duration of the study. All clinical and laboratory parameters establishing the clinical, functional and radiological outcomes in these patients over 5 yr, for two gold improved, with~30-50% improvement in CRP, ESR, Ritchie Index and joint stiffness for each of the four preparations which continue to be prescribed in clinical practice, will be useful to clinicians [19, 46, 47] . drugs. The number of intra-articular steroid injections was similar for all four drugs. Functional ability
The median disease duration prior to prescribing the first DMARD was 2 yr which, although relatively late improved slightly, with the exception of patients on i.m. gold. The radiology Larsen score, which combined compared to current recommendations [2, 48] , is still in keeping with the trend at that time towards earlier new joint involvement and progression of pre-existing joint damage, deteriorated to a similar extent in all prescribing of DMARDs [49] , and the report that almost 80% of patients had received their first groups.
DMARD within 2 yr [50] . The study protocol encour-DISCUSSION aged the physician to persist with the first randomized drug unless the trial criteria for lack or loss of effect Defining a satisfactory outcome measure of treatment in a disease of such variable expression, in terms were fulfilled, or an adverse reaction developed. The principle of re-introducing a DMARD in reduced out rate due to adverse reactions was 42% [8] , and 54% in the Multicentre Trial Group Study [54] . In the dosage after resolution of a minor drug reaction was applied equally to each DMARD, but in practice Multicentre Study, seven out of 15 patients who stopped penicillamine due to an adverse reaction were almost all of those re-challenged were receiving either gold or penicillamine.
receiving between 750 and 1000 mg daily. Our graduated low-dose flexible regimen may have been a conThe dosage regimens for each DMARD were flexible, and the principle of prescribing the lowest dose tributing factor in restricting the withdrawals due to adverse reactions to 20% at 5 yr. As almost all of these consistent with good control of disease activity was applied to each DMARD. For patients taking hydroxypatients were withdrawn in <2 yr on treatment, this figure is comparable to the drop-out rate of 21% over chloroquine, sodium aurothiomalate and auranofin, the dosages for patients who were still on the same 18 months in the European multicentre study in which the majority of patients received 500 mg penicillamine DMARD after 5 yr were close to the maximum recommended in clinical practice. By contrast, the mean daily [55] . It is also close to the drop-out rate of 22% for patients who received 500 mg daily in the low-dose daily dosage of penicillamine after 5 yr was only 396 mg, which is less than the currently recommended 30 week trial reported by Williams et al. [56 ] . In our study, if flexibility had allowed an increase up to the minimum of 500 mg daily [51] .
The decision to limit the dose of penicillamine to currently recommended maximum of 1000 mg daily [51] , instead of being limited to 500 mg daily, this 500 mg a day was taken in response to reports which demonstrated that slow incremental increases in penimight have improved the response rate, but at the possible expense of an increase in toxicity. cillamine to a maximum of 500 or 600 mg daily could produce a clinical response comparable to that
This was an open study, with the potential for observer bias in favour of one particular drug. achieved with higher doses, but with less risk of toxicity [42, 52] . There is marked individual variation in the However, the data in Table V demonstrate comparable improvements in almost all of the mean changes in response to DMARDs [2] , and some patients will respond well taking <500 mg penicillamine a day [53] .
clinical, laboratory and functional assessments after 5 yr, and provide no evidence of prolonged or inapproIn our study, 54 of the 94 patients who remained on penicillamine for 5 yr needed 500 mg a day to produce priate treatment with any one DMARD. The minimum dosage regimen adopted for penicillamine in the trial a satisfactory clinical response, 30 patients responded to lower doses, and for 10 others it was possible to protocol could have limited the degree of improvement by producing a less than optimal response in some reduce the dose below 500 mg over time without evidence of a relapse.
patients. Although the patients on penicillamine had the least amount of improvement in CRP, ESR, Ritchie Although adverse reactions to penicillamine can appear at any time, there is a dose relationship to the Index, pain scores and combined grip strength, the differences are small, and not sufficient to account for frequency of side-effects [51] . In a meta-analysis of the toxicity of DMARDs [22], the drop-out rate for the large differences in the proportion continuing on penicillamine by comparison with the other DMARDs patients who received penicillamine in a daily dose range between 500 and 1250 mg was 30%, but the at 5 yr ( Fig. 1) . The study recruited a representative set of patients mean duration of follow-up was only 37 weeks, which excluded late toxicity. In two 5 yr studies which permitreferred for second-line therapy. The design reflected routine clinical practice in the 1980s as closely as ted dosages between 125 and 1000 mg daily, the drop-possible by allowing a flexible approach to drug dosage be higher than for subsequent courses [59] . At 5 yr, regimens, and a change of treatment in the event of our results showed similar continuation rates for therapeutic failure. Intra-articular steroid injections sodium aurothiomalate (34%) as for those with equivawere permitted, but the number of injections per lent disease duration described by Munro et al. [64] . patient per year in each group of DMARDs was Similarly, our results for sodium aurothiomalate and comparable and not excessive ( Table V ) . No patients for hydroxychloroquine (30%) compared well with received i.m. injections of depot corticosteroid.
those reported by Pincus [59] . In that clinical study, Functional and radiological assessments were incorpanalysis of all courses of DMARDs over 5 yr was orated, and the patients were monitored for 5 yr. These permitted, which may have contributed to differences considerations overcome many of the reservations conin continuation on auranofin (31%) in our study comcerning the use of randomized controlled trials in pared with only 10%, and continuation on penicillam-RA [21] .
ine (53%) compared with 20%. The unexpectedly high Direct comparison of our results with other studies continuation rate on penicillamine in our study is is not possible, because randomized controlled trials comparable to the 5 yr continuation rate reported for involving these four DMARDs have not been consulphasalazine [65] , and is most probably explained tinued for longer than 2 yr. However, comparison with by our low dosage regimen, as the clinicians were long-term observational studies [57] [58] [59] shows that the unaware of the superiority of penicillamine until results pattern of DMARD withdrawal over 5 yr was similar, had been analysed after completion of the study. with the highest failure rate during the first 2 yr of This paper has focused on the outcome over 5 yr of treatment (Fig. 1) . At 2 yr, the probability of our patients randomized to their first DMARD between patients still being on treatment was as follows: hydroxy-1981 and 1989, and has provided good evidence that chloroquine (48%), penicillamine (69%), sodium auropenicillamine in a maximum dose of 500 mg a day has thiomalate (53%) and auranofin (50%). These results advantages over hydroxychloroquine and auranofin in are comparable to other 2 yr studies which had a terms of continuation on treatment over 5 yr, and has similar clinical emphasis with regard to hydroxychloroadvantages over injectable gold in terms of toxicity. quine 46% [18] , sodium aurothiomalate 45% [19] and
The introduction of sulphasalazine, immunosuppresauranofin 46% [60] . In a 2 yr study of penicillamine sive drugs and biologicals, the earlier use of combinaand sulphasalazine, only 40% of patients were still on tion therapy in aggressive RA [66 ] , new data on the penicillamine after 2 yr [61] . The longer disease durause of oral prednisolone in low dose [67] and in high tion, a dose regimen which permitted an increase to dose [68] for the treatment of early RA, are all attempts 1000 mg a day, previous exposure to DMARDs and to find more effective and safer treatments that will greater functional disability in this study group could radically improve the outcome for patients over 20 yr. have contributed to the less favourable outcome.
Evidence that these newer regimens will continue to The withdrawal rate for lack of effect at 5 yr in our be more effective and safer than the commonly prestudy was highest for hydroxychloroquine (49%) and scribed DMARDs in conventional monotherapy auranofin (36%), which is consistent with the current dosage regimens is needed, but the 5 yr data from this recommendations for reserving these DMARDs for study will provide a valuable resource against which patients with mild, slowly progressive disease [2] . The results of future 5 yr trials using new drugs and new withdrawal rates for lack of effect for sodium aurothioapproaches can be judged. malate (22%) and penicillamine (19%) were almost identical. The higher proportion of patients who were A still taking penicillamine at 5 yr (53%) compared with
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